Oncology | Phase III Developments | SPAIN

PharmaMar

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SPAIN Spain

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

PharmaMar and Megapharm sign a licensing agreement for lurbinectedin in Israel

Lead Product(s): Lurbinectedin

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Megapharm

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement May 11, 2020

Details:

This new agreement will allow lurbinectedin to reach the Israeli market, if approved, in the hands of one of the leading companies in the field of oncology in this country.

Isofol Medical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SPAIN Spain

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Isofol's Drug Candidate Arfolitixorin Receives Additional Clinical Patent Approval in the United States

Lead Product(s): Arfolitixorin,Oxaliplatin,Fluorouracil

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 05, 2020

Details:

The granted patent is focused on the ongoing global Phase 3 study AGENT with arfolitixorin demonstrating potential superior activity for arfolitixorin and 5-fluorouracil treatment.

Isofol Medical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SPAIN Spain

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

The First Patient Included in Japan in Isofol's Phase 3 AGENT Study

Lead Product(s): Arfolitixorin,Oxaliplatin,Fluorouracil

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 18, 2020

Details:

Isofol's drug candidate arfolitixorin is being evaluated in the first line of treatment of metastatic colorectal cancer (mCRC) in the USA, Canada, Europe, Australia and now also in Japan.

Isofol Medical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SPAIN Spain

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

The First Patient Included in Australia in Isofol's Phase 3 AGENT Study

Lead Product(s): Arfolitixorin,Oxaliplatin,Fluorouracil

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 24, 2020

Details:

Isofol's drug candidate arfolitixorin is being evaluated in the first line of treatment of metastatic colorectal cancer (mCRC).

PharmaMar

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SPAIN Spain

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting...

Lead Product(s): Lurbinectedin

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Jazz Pharmaceuticals

Deal Size: $1,000.0 million Upfront Cash: $200.0 million

Deal Type: Licensing Agreement January 22, 2020

Details:

PharmaMar & Jazz signed an exclusive license agreement for U.S. rights to lurbinectedin, the effectiveness of which was subject to the expiration or early termination of the applicable HSR waiting period.

Find

Find Oncology Drugs in Phase III Clinical Development in SPAIN

Spain

Product Type

Companies

PharmaMar

PharmaMar and Megapharm sign a licensing agreement for lurbinectedin in Israel

Isofol Medical

Isofol's Drug Candidate Arfolitixorin Receives Additional Clinical Patent Approval in the United States

Isofol Medical

The First Patient Included in Japan in Isofol's Phase 3 AGENT Study

Isofol Medical

The First Patient Included in Australia in Isofol's Phase 3 AGENT Study

PharmaMar

PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting...